Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Longhorn Vaccines And Diagnostics LLC maintains a concentrated patent portfolio within the Biotechnology & Pharmaceuticals technology area. The current prosecution activity is focused, as evidenced by 1 pending office action. This action represents the entirety of the company's immediate administrative requirements before the patent office, suggesting a streamlined filing strategy that prioritizes specific intellectual property assets over a high volume of simultaneous applications.
The examination landscape for this portfolio is characterized by a high degree of specificity. There is 1 distinct examiner assigned to the pending matters, operating within a distinct art unit. Such a narrow distribution indicates that the company's current legal challenges are confined to a technical niche and a specific point of contact within the regulatory body. This lack of diversity in art units simplifies the procedural overhead for the applicant, as there is no need to reconcile differing examiner styles or conflicting art unit guidelines.
GRIZER, CASSANDRA SENN is identified as the busiest examiner for this portfolio. This individual is responsible for the busiest examiner pending office action. For a practitioner, this means that the outcome of the company's current prosecution efforts rests entirely on the evaluation of GRIZER, CASSANDRA SENN. The alignment between the total pending actions and those assigned to the busiest examiner confirms that there are no other active examiners currently reviewing the company's applications, allowing for a very direct prosecution path.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GRASER, JENNIFER E | 1 | 76.8% | +23.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18162032 | Immunogenic Antigens | GRASER, JENNIFER E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18162032 | Immunogenic Antigens | GRASER, JENNIFER E | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18162032 | Immunogenic Antigens | GRASER, JENNIFER E | 1645 | §102§112 | Final Rejection | — | Pending | Jan 31, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLonghorn Vaccines And Diagnostics LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jennifer E Graser has the most, with 1 of Longhorn Vaccines And Diagnostics LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
